Topic Compilations

Topic Compilations

Each of our Topic Compilations includes a collection of features and news articles published in ASH Clinical News related to a specific hematologic disorder.

China First to Approve Oral Drug to Stimulate Erythropoiesis

China’s National Medical Products Administration approved the oral anemia drug roxadustat, well before regulators in the U.S. or Europe have issued decisions. The hypoxia-inducible...

FDA Approves Calaspargase Pegol-mknl for Acute Lymphocytic Leukemia

The U.S. Food and Drug Administration approved calaspargase pegol-mknl as part of a multi-agent chemotherapy regimen for the treatment of pediatric and young adult...
WIB_icon

Duvelisib Bests Ofatumumab in Relapsed and Refractory CLL/SLL

In the phase III DUO trial, treatment with the oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib improved progression-free survival (PFS) and overall response, compared...

Ibrutinib Versus FCR: A “Paradigm Shift” for Younger Patients With Treatment-Naïve CLL

In patients with previously untreated chronic lymphocytic leukemia (CLL), treatment with an ibrutinib-based therapy improved progression-free survival (PFS) and overall survival (OS), compared with...

Is Daratumumab Plus Lenalidomide-Dexamethasone a New Standard for Transplant-Ineligible Myeloma?

Adding daratumumab to standard combination of lenalidomide and dexamethasone (Rd) reduced the risk of disease progression and death by 44 percent in patients with...

Weighing Conditioning Regimens for Patients With CML Undergoing Transplant

Conditioning with a reduced-intensity, nonmyeloablative regimen was associated with similar post-transplant survival but a lower risk of chronic graft-versus-host disease (cGVHD), compared with a...

FDA Approves Elotuzumab-Based Triplet Regimen for Myeloma

The FDA approved the combination of elotuzumab plus pomalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (MM)...

How I Treat in Brief: Using Molecular Genetic Tests to Evaluate Myelodysplastic Syndromes

David P. Steensma, MD, of Dana-Farber Cancer Institute and Harvard Medical School in Boston, discussed how to use results from molecular genetic tests in...

FDA Approves New Hemophilia A Drug

The FDA has approved emicizumab-kxwh as prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A...

How I Treat in Brief: Managing Post-Thrombotic Syndrome

Anat Rabinovich, MD, of Soroka University Medical Center at the Ben-Gurion University of the Negev in Israel and Susan R. Kahn, MD, MSc, of...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.